Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.090
Sell
RSI(14)
36.785
Neutral
STOCH(KDJ)(9,3,3)
59.113
Buy
ATR(14)
0.235
Low Volatility
CCI(14)
-22.818
Neutral
Williams %R
75.986
Sell
TRIX(12,20)
-0.990
Sell
StochRSI(14)
100.000
Overbought
Bausch Health Companies Inc
BHC5.880USD
+0.150+2.62%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.18BMarket Cap
6.01P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Bausch Health Companies Inc
Currency: USD Updated: 2026-02-06Key Insights
Bausch Health Companies Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 83 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 7.71.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bausch Health Companies Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Bausch Health Companies Inc Highlights
StrengthsRisks
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.48% year-on-year.
Overvalued
The company’s latest PE is 6.01, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 175.10M shares, increasing 0.03% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.72.
Analyst Rating
Based on
7
analysts
Hold
Current Rating
7.714
Target Price
+34.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Bausch Health Companies Inc is 8.49, ranking 64 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 2.68B, representing a year-over-year increase of 6.81%, while its net profit experienced a year-over-year increase of 310.59%.
Score
Financials
5.31
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.50
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.66
Bausch Health Companies Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Bausch Health Companies Inc is 5.04, ranking 154 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 6.01, which is 423.87% below the recent high of 31.47 and 1173.43% above the recent low of -64.48.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 83/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Bausch Health Companies Inc is 5.71, ranking 142 out of 159 in the Pharmaceuticals industry. The average price target is 7.00, with a high of 10.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Hold
Current Rating
7.714
Target Price
+34.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Bausch Health Companies Inc
BHC
7
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Bausch Health Companies Inc is 6.78, ranking 105 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.33 and the support level at 4.99, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
5.746
Buy
MA10
5.724
Buy
MA20
6.362
Sell
MA50
6.758
Sell
MA100
6.594
Sell
MA200
6.333
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Meruelo (Alex)
GoldenTree Asset Management, LP
Nomura Securities Co., Ltd.
Healthcare Of Ontario Pension Plan
National Bank of Canada
MFN Partners Management LP
Kohlberg Kravis Roberts & Co. L.P.
RBC Brewin Dolphin
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bausch Health Companies Inc is 6.07, ranking 61 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.35
VaR
+5.19%
240-Day Maximum Drawdown
+43.90%
240-Day Volatility
+53.85%
Return
Best Daily Return
60 days
+11.02%
120 days
+12.03%
5 years
+24.09%
Worst Daily Return
60 days
-10.05%
120 days
-10.05%
5 years
-41.24%
Sharpe Ratio
60 days
-1.03
120 days
-0.68
5 years
-0.26
Risk Assessment
Maximum Drawdown
240 days
+43.90%
3 years
+59.28%
5 years
+86.77%
Return-to-Drawdown Ratio
240 days
-0.41
3 years
-0.10
5 years
-0.19
Skewness
240 days
+0.68
3 years
+0.22
5 years
-0.88
Volatility
Realised Volatility
240 days
+53.85%
5 years
+65.72%
Standardised True Range
240 days
+4.86%
5 years
+8.13%
Downside Risk-Adjusted Return
120 days
-123.54%
240 days
-123.54%
Maximum Daily Upside Volatility
60 days
+43.35%
Maximum Daily Downside Volatility
60 days
+31.35%
Liquidity
Average Turnover Rate
60 days
+0.83%
120 days
+0.70%
5 years
--
Turnover Deviation
20 days
+72.45%
60 days
+15.02%
120 days
-2.69%
Peer Comparison
Pharmaceuticals
Bausch Health Companies Inc
BHC
6.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
